Trump talk: President-elect's promise to control drug prices tanks biotech stocks

Biotech stocks fell nearly 5 percent Dec. 7, after Time magazine published an interview with President-elect Donald Trump, in which he vowed to take action to control drug prices.

Considering widespread concern over drug prices and recent high-profile cases of specific price increases, Trump appears to be including promises to control pharmaceutical prices in his populist message. In the interview with Time, which named him its "Person of the Year" for 2016, the president-elect was typically straightforward in his message.

“I’m going to bring down drug prices,” Trump said to Time. “I don’t like what has happened with drug prices.”

Biotech stocks fell by 4.6 percent in the hours after the story was published. The Nasdaq Biotechnology Index hit its low of 261.65 at 11:25 a.m. (EST) before making a slight recovery.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.